Sedat ALTIN, Adalet DEMİR, S. İbrahim DİNÇER, Vedat KÖKSAL, İsrafil DEMİR, Ümran ÇETİNÇELİK

The role of CYP1A1 Msp1 gene polymorphisms on lung cancer development in Turkey

Sitokrom P450 1A1 (CYP1A1) metabolik enzimlerini kodlayan genlerdeki polimorfizm, kişilerin akciğer kanserine olan duyarlılığındaki değişikliklere katkıda bulunuyor olabilir. CYP1A1’in akciğer karsinogenezindeki rolü, düşük düzeyli karsinojen maruziyetinde daha da önemli olabilir. Çalışmamızda CYP1A1 gen polimorfizmi, sağlıklı ve akciğer kanserli Türk popülasyonunda araştırıldı. Bu vaka kontrol çalışmasına 31 akciğer kanserli hasta ve randomize olarak seçilen 37 sağlıklı birey kontrol grubu olarak alındı. DNA örnekleri tam kandan alındı ve polimeraz zincir reaksiyonu (PCR) ile çoğaltıldı. CYP1A1 Msp1 (-/+ veya +/+) polimorfizm prevalansı akciğer kanserli hastalarda %19.4; buna karşın kontrol grubunda %16.2 idi ve fark istatistiksel olarak anlamlı bulunmadı (OR= 1.24, 95%CI= 0.36-4.32, p= 0.74). Akciğer kanserinin histopatolojik analizinde histopatolojik tip ile CYP1A1 Msp1 polimorfizmi arasında bir ilişki saptanmadı (p= 0.6). Spesifik biyomarkerlar kullanılarak yapılan genetik çalışmaların akciğer kanser riskinin izlenmesinde yararlı olacağı umut edilir. Güvenli ve doğru istatistiksel bilgiler için çok merkezli kohort çalışmalara ihtiyaç vardır.

Türk popülasyonunda CYP1A1 Msp1 gen polimorfizminin akciğer kanseri gelişimindeki rolü

Polymorphisms for genes encoding the metabolic enzymes cytochrome P450 1A1 (CYP1A1) might contribute to the variability in individual susceptibility to lung cancer. The role of CYP1A1 in lung carcinogenesis might be more important at low levels of exposure to carcinogens. In our study, CYP1A1 gene polymorphisms were investigated in healthy subjects and lung cancer patients in Turkish population. This case-control study encompassed 31 lung cancer patients and randomly selected 37 healthy individuals in control group. DNA samples, extracted from the whole blood were amplified using polymerase chain reaction (PCR) method. The prevalence of CYP1A1 Msp1 (-/+ or +/+) polymorphism in the lung cancer patients was 19.4%, compared to 16.2% in control group but the result was not statistically significant (OR= 1.24, 95% CI= 0.36-4.32, p= 0.74). Another important result obtained in this study is that 16.2% of Turkish population carries a CYP1A1 Msp1 polymorphism. The analysis of patients by histological type of lung cancer showed no association between histopathologic type of lung cancer and CYP1A1 Msp1 polymorphism (p= 0.6). Genetic researches using specific biomarkers are expected to be helpful in monitorizing the risk of lung cancer. Multicenter cohort studies are necessary to be able to obtain reliable and correct statistical information.

PDF

___

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide (1.0), Cancer Base no. 5. IARC, Lyon, France, 2001.
2. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999; 49: 33-64.
3. Perera FP. Molecular epidemiology of environmental carcinogenesis. Recent Results Cancer Res 1998; 154: 39-46.
4. Raunio H, Husgafvel-Pursiainen K, Anttila S, et al. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility. Gene 1995; 159: 113-21.
5. Daly AK, Cholerton S, Armstrong M, Idle JR. Genotyping for polymorphisms in xenobiotic metabolism as a predictor of disease susceptibility. Environ Health Perspect 1994; 102: 55-61.
6. Kawajiri K, Nakachi K, Imai K, et al. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett 1990; 263: 131-3.
7. Le Marchand L, Sivaraman L, Pierce L, et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res 1998; 58: 4858-63.
8. Xu X, Kelsey KT, Wiencke JK, et al. Cytochrome P450 CYP1A1 MspI polymorphism and lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1996; 5: 687-92.
9. Mooney LA, Bell DA, Santella RM, et al. Contribution of genetic and nutritional factors to DNA damage in heavy smokers. Carcinogenesis 1997; 18: 503-9.
10. Bartsch H, Nair U, Risch A, et al. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol Biomarkers Prev 2000; 9: 3-28.
11. Wu MT, Huang SL, Ho CK, et al. Cytochrome P4501A1 Msp1 polymorphism and urinary 1-hydroxipyrene concentrations in coke-owen workers. Cancer Epidemiol Biomarkers Prev 1998; 7: 823-9.
12. Strong LC, Amos CI. Inherited susceptibility. Cancer Epidemiology and Prevention. New York: Oxford University Press, 559-82.
13. Taioli E, Gaspari L, Benhamou S, et al. Polymorphisms in CYP1A1, GSTM1, GSTT1 and lung cancer below the age of 45 years. Int J Epidemiol 2003; 32: 60-3.
14. Hung RJ, Boffetta P, Brockmoller J, et al. CYP1A1 and GSTM1 genetic polymorphisms and lung cancer risk in Caucasian non-smokers: a pooled analysis. Carcinogenesis 2003; 24: 875-82.
15. Kawajiri K, Eguchi H, Nakachi K, et al. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res 1996; 56: 72-6.
16. Spivack SD, Fasco MJ, Walker VE, Kaminsky LS. The molecular epidemiology of lung cancer. Crit Rev Toxicol 1997; 27: 319-65.
17. Ambrosone CB, Freudenheim JL, Graham S, et al. Cytochrome P4501A1 and glutathione S-transferase (M1) genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 1995; 55: 3483-5.
18. Quinones L, Berthou F, Varela N, et al. Ethnic susceptibility to lung cancer: differences in CYP2E1, CYP1A1 and GSTM1 genetic polymorphisms between French Caucasian and Chilean populations. Cancer Lett 1999; 141: 167-71.
19. Schoket B, Phillips DH, Kostic S, Vincze I. Smoking-associated bulky DNA adducts in bronchial tissue related to CYP1A1 MspI and GSTM1 genotypes in lung patients. Carcinogenesis 1998; 19: 841-6.
20. Ozturk O, Isbir T, Yaylim I, et al. GST M1 and CYP1A1 gene polymorphism and daily fruit consumption in Turkish patients with non-small cell lung carcinomas. In Vivo 2003; 17: 625-32.
21. Ozbek U, Aydın M, Hatırnaz O, et al. Metabolising Enzyme Polymorphisms (GSTM1, GSTT1, CYP1A1, CYP2D6) and Their Association as a Potential Susceptibility to Pediatric ALL. American Society of Hematology 43rd Annual Meeting and Exposition. December 7-11, 2001, Orlondo, FL.
22. Aynacioglu AS, Cascorbi I, Mrozikiewicz PM, Roots I. High frequency of CYP1A1 mutations in a Turkish population. Arch Toxicol 1998; 72: 215-8.
23. Taioli E, Ford J, Trachman J, et al. Lung cancer risk and CYP1A1 genotype in African Americans. Carcinogenesis 1998; 19: 813-7.
24. Smith GB, Harper PA, Wong JM, et al. Human lung microsomal cytochrome P4501A1 (CYP1A1) activities: impact of smoking status and CYP1A1, aryl hydrocarbon receptor, and glutathione S-transferase M1 genetic polymorphisms. Cancer Epidemiol Biomarkers Prev 2001; 10: 839-53.